Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

or RAPAFLO(R) 4 mg, 13.3 percent for RAPAFLO(R) 8 mg, and 1.9 percent for placebo.

Study Design

The double-blind, 12-week, placebo-controlled Phase 2 study evaluated the safety and efficacy of RAPAFLO(R) in patients with moderate to severe non-bacterial CP/CPPS who previously had not received alpha-blockers for the condition.  Patients with National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score >/=15 (moderate to severe), NIH-CPSI pain score >/=8 (mild to moderate), and pelvic pain for >/=3 months before screening were randomized to RAPAFLO(R) 4 mg or 8 mg per day, or placebo. The primary measure of efficacy was improvement in the NIH-CPSI total score. Of 151 participants, 76.2 percent completed the study. The median age of patients was 48.2 years; 80.1 percent had experienced pain for at least one year.

Secondary end points evaluated were: safety; change from baseline in NIH-CPSI pain, urinary, and quality of life scores; and change from baseline in Medical Outcomes Study Short Form 12 (SF-12) physical and mental component scores. Additional secondary end points were percentages of participants who had a sufficiently significant decrease in total score (NIH-CPSI responders) and of those who indicated "markedly improved" or "moderately improved" on the global response assessment (GRA) scale (GRA responders).

About RAPAFLO(R) (silodosin)

RAPAFLO(R) was first approved by the FDA two years ago for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO(R) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(R) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alp
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Research and ... Electronics Market by Material, by Application, Geography - Global ... their offering. Organic electronics, also called ... of material science which deals with small conductive molecules ... because small molecules and polymers are carbon based, made ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 ... announced that a team from Iowa State University won ... design contest. Using a Convey HC-2ex, the team’s solution ... 14 times faster than the second place finisher. , ... world embarked upon the month long challenge, using a ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Physicians at Thomas Jefferson University Hospital reported today on ... automated interpretation of coronary CT angiography (cCTA) by Rcadia,s ... disease (CAD) in the major coronary arteries as well ... at the Radiological Society of North America (RSNA) Annual ...
... caught up with Gerhard Welsch,s ideas. Welsch, a professor ... began patenting designs for a small, light, powerful and reliable ... energy storage device makers of hybrid cars, computer power supplies, ... of electricity. Funded with a recent $2.25 million stimulus ...
... York, NY November 29, 2010 In 2008, ... Applied Science at Columbia University established pure graphene, a ... the strongest material known to mankind. This raised a ... Department of Applied Physics and Applied Mathematics: ...
Cached Biology Technology:Rcadia COR Analyzer System Safely Rules Out Coronary Artery Disease in Main Coronary Arteries and Branch Vessels 2Time ripe to move energy storage idea off drawing board 2Columbia engineering team discovers graphene's weakness 2
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... Virology is now the official publication of the ... The new affiliation takes effect immediately. The journal, founded ... by Medline, the U.S. National Library of Medicine,s bibliographic ... original articles, notes and reviews on research relating to ...
... BOSTONParkinson,s disease (PD) is a progressive degenerative disease affecting ... movement. What starts out as a tremor in a ... speaking, and ultimately the inability to walk without assistance. ... Parkinson,s have decreased levels of the chemical dopamine in ...
... grow collections of abnormal blood cells, the fuel that feeds ... an animal model suggests that blood vessels in the fat ... provide the key to a new way for people to ... Chinchar, Carissa Howie, and Lucio Miele, all from the University ...
Cached Biology News:Food and Environmental Virology adds society affiliation 2New research examines connection between inflammatory stimulus and Parkinson's disease 2New research examines connection between inflammatory stimulus and Parkinson's disease 3Drug reduces fat by blocking blood vessels 2Drug reduces fat by blocking blood vessels 3
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
CELLine System cultivation flask (for secreted products)...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
... Immunodepletion Kit specifically removes 20 of the ... serum in preparation for further proteomics analysis. ... plasma proteome whether you use one- or ... go straight to mass spectrometry. This is ...
Biology Products: